Competitor Analysis: Interleukin-23 & IL-12/23 Antagonists, New Report Launched

The Competitive Intelligence report about Interleukin-23 (IL-23) and IL-12/23 antagonists provides a competitor analysis of approved or being developed novel antagonists of interleukin-23 and IL-12/23 (p40 subunit) for treatment of psoriasis and other inflammatory diseases as of September 2015. Purchase of the pdf report includes a 6-month online access to the data of the report and any updates since the publication date. Credentials to access the database will be sent by e-mail and allow online work with the project data to print or export an individual report.

The report provides a compilation of active products and projects on the market or in research and development as specific IL-23 or IL-12/23 (p40) antagonists as well as dual target IL-23 antagonists for treatment of immunologic diseases.

Competitor projects are listed in a tabular format providing information on:

• Drug Codes
• Target / Mechanism of Action
• Class of Compound
• Company
• Product Category
• Indication,
• R&D Stage and
• additional comments with a hyperlink leading to the source of information.

Spanning over 16 pages “Competitor Analysis: Interleukin-23 & IL-12/23 Antagonists” report covers IL-12/23 (p40) Antagonists, Selective IL-23 Antagonists, Dual Target IL-23 Antagonists, Corporate IL-23 & IL-12/23 R&D Portfolios.

For further information on this report, please visit- http://mrr.cm/oMS

Find all Therapeutic Reports at: http://www.marketresearchreports.com/therapeutic

Related Reports:

Competitor Analysis: Sphingosine-1-Phosphate (S1P) Receptor Modulators - visit at: http://mrr.cm/oMT

Competitor Analysis: Interleukin-4/-13 (IL-4/-13) Inhibitors or Receptor Antagonists - visit at: http://mrr.cm/oMq

Competitor Analysis: Amyloid beta- and Tau-Targeted Antibodies & Vaccines - visit at: http://mrr.cm/oMc